Vitreous Levels of Erythropoietin and Vascular Endothelial Growth Factor in Eyes with Retinopathy of Prematurity
Authors:
- Shunji KusakaSKShunji Kusaka
- 1 September 2009
- journal article
- Published by Elsevier in Ophthalmology
- Vol. 116 (9) , 1599-1603
Abstract
No abstract availableKeywords
Funding Information
- Ministry of Education, Culture, Sports, Science and Technology (17591832, 20592041)
This publication has 19 references indexed in Scilit:
- Efficacy of intravitreal injection of bevacizumab for severe retinopathy of prematurity: a pilot studyBritish Journal of Ophthalmology, 2008
- INTRAVITREAL INJECTION OF BEVACIZUMAB (AVASTIN) FOR TREATMENT OF STAGE 3 RETINOPATHY OF PREMATURITY IN ZONE I OR POSTERIOR ZONE IIRetina, 2008
- Vitreous Levels of Stromal Cell–Derived Factor 1 and Vascular Endothelial Growth Factor in Patients with Retinopathy of PrematurityOphthalmology, 2008
- Erythropoietin: A Candidate Neuroprotective Agent in the Treatment of GlaucomaJournal of Glaucoma, 2007
- Retinopathy of prematurityAngiogenesis, 2007
- Erythropoietin Concentrations and Neurodevelopmental Outcome in Preterm InfantsPediatrics, 2006
- Erythropoietin Is Expressed in the Human Retina and It Is Highly Elevated in the Vitreous Fluid of Patients With Diabetic Macular EdemaDiabetes Care, 2006
- Erythropoietin as a Retinal Angiogenic Factor in Proliferative Diabetic RetinopathyNew England Journal of Medicine, 2005
- Angiogenic Pathways in Diabetic RetinopathyNew England Journal of Medicine, 2005
- Erythropoietin protects the in vitro blood–brain barrier against VEGF‐induced permeabilityEuropean Journal of Neuroscience, 2003